 |
|
|
| |
Open label, randomized, crossover, single-dose, bioavailability evaluation of atazanavir/ritonavir FDC tablets 300 mg/100 mg with that of REYATAZ 300 mg and NORVIR 100 mg under fed and fasting conditions
|
| |
| |
Reported by Jules Levin
20th International AIDS Conference, July 20-25, 2014, Melbourne
I. Bhushan1, A. Deshmukh1, S. Chakraborty1, A. Dixit1, P. Shetiya1, U. Kothawade1, A. Kanda2,
P. Deshpande2, E. Patras2, R. Satapthy1
1MYLAN Laboratories Ltd., Research & Development, Hyderabad, India
2MYLAN Laboratories Ltd., Business Development, Hyderabad, India
|
| |
|
|
|
|
|
